Dianthus Therapeutics (DNTH) Short Interest Ratio & Short Volume $20.77 -1.50 (-6.74%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Dianthus Therapeutics Short Interest DataDianthus Therapeutics (DNTH) has a short interest of 5.10 million shares, representing 25.20% of the float (the number of shares available for trading by the public). This marks a 7.82% increase in short interest from the previous month. The short interest ratio (days to cover) is 26.6, indicating that it would take 26.6 days of the average trading volume of 304,195 shares to cover all short positions.Current Short Interest5,100,000 sharesPrevious Short Interest4,730,000 sharesChange Vs. Previous Month+7.82%Dollar Volume Sold Short$142.09 millionShort Interest Ratio26.6 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares29,600,000 sharesFloat Size20,240,000 sharesShort Percent of Float25.20%Today's Trading Volume194,955 sharesAverage Trading Volume304,195 sharesToday's Volume Vs. Average64% Short Selling Dianthus Therapeutics? Sign up to receive the latest short interest report for Dianthus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDNTH Short Interest Over TimeDNTH Days to Cover Over TimeDNTH Percentage of Float Shorted Over Time Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Dianthus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20245,100,000 shares $142.09 million +7.8%25.2%26.6 $27.86 10/15/20244,730,000 shares $130.26 million -4.8%23.6%22.6 $27.54 9/30/20244,970,000 shares $136.08 million +14.8%24.8%24.6 $27.38 9/15/20244,330,000 shares $125.40 million +0.7%21.6%17.2 $28.96 8/31/20244,300,000 shares $123.97 million +5.9%21.4%16.1 $28.83 8/15/20244,060,000 shares $121.03 million +10.9%20.2%15 $29.81 7/31/20243,660,000 shares $108.99 million +9.6%17.9%14 $29.78 7/15/20243,340,000 shares $96.86 million +42.7%16.3%13.6 $29.00 6/30/20242,340,000 shares $60.56 million +18.8%11.4%9.5 $25.88 6/15/20241,970,000 shares $51.22 million -5.3%9.6%10.6 $26.00 5/31/20242,080,000 shares $44.95 million No Change10.2%13.2 $21.61 5/15/20242,080,000 shares $57.60 million -3.3%10.2%13 $27.69 4/30/20242,150,000 shares $45.90 million +12.6%10.0%12.6 $21.35 4/15/20241,910,000 shares $48.27 million +37.4%8.9%11.5 $25.27 3/31/20241,390,000 shares $41.70 million +29.9%6.5%9.8 $30.00 3/15/20241,070,000 shares $30.01 million +27.3%5.0%8.4 $28.05 2/29/2024840,400 shares $20.80 million +135.9%6.1%8.7 $24.75 2/15/2024356,200 shares $8.51 million +274.2%2.6%4.4 $23.89 1/31/202495,200 shares $1.81 million No Change1.1%1.8 $19.00 DNTH Short Interest - Frequently Asked Questions What is Dianthus Therapeutics' current short interest? Short interest is the volume of Dianthus Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 5,100,000 shares of DNTH short. 25.20% of Dianthus Therapeutics' shares are currently sold short. Learn More on Dianthus Therapeutics' current short interest. What is a good short interest ratio for Dianthus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DNTH shares currently have a short interest ratio of 27.0. Learn More on Dianthus Therapeutics's short interest ratio. What is a good short interest percentage for Dianthus Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 25.20% of Dianthus Therapeutics' floating shares are currently sold short. Is Dianthus Therapeutics' short interest increasing or decreasing? Dianthus Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 5,100,000 shares, an increase of 7.8% from the previous total of 4,730,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Dianthus Therapeutics' float size? Dianthus Therapeutics currently has issued a total of 29,600,000 shares. Some of Dianthus Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Dianthus Therapeutics currently has a public float of 20,240,000 shares. How does Dianthus Therapeutics' short interest compare to its competitors? 25.20% of Dianthus Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Dianthus Therapeutics: Amneal Pharmaceuticals, Inc. (2.92%), Scholar Rock Holding Co. (16.36%), Zai Lab Limited (4.68%), Janux Therapeutics, Inc. (10.18%), Catalyst Pharmaceuticals, Inc. (5.84%), Iovance Biotherapeutics, Inc. (24.07%), Twist Bioscience Co. (15.20%), Longboard Pharmaceuticals, Inc. (5.70%), Arrowhead Pharmaceuticals, Inc. (7.55%), Protagonist Therapeutics, Inc. (5.50%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Dianthus Therapeutics stock? Short selling DNTH is an investing strategy that aims to generate trading profit from Dianthus Therapeutics as its price is falling. DNTH shares are trading down $1.50 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Dianthus Therapeutics? A short squeeze for Dianthus Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of DNTH, which in turn drives the price of the stock up even further. How often is Dianthus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DNTH, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Amneal Pharmaceuticals Short Interest Scholar Rock Short Interest Zai Lab Short Interest Janux Therapeutics Short Interest Catalyst Pharmaceuticals Short Interest Iovance Biotherapeutics Short Interest Twist Bioscience Short Interest Longboard Pharmaceuticals Short Interest Arrowhead Pharmaceuticals Short Interest Protagonist Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DNTH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.